Gilead to acquire Tubulis
Tubulis GmbH, a 2019 German university spin-out, is to be acquired by Gilead Inc for up to $5 billion – one of the larger biopharma transactions in Europe this year. Announced on 7 April, the deal involves an upfront payment of $3.15 billion and potential milestones of $1.85 billion for ownership of an early clinical-stage portfolio of antibody-drug conjugates (ADCs) for cancer. As part of the agreement, Tubulis’ scientists and other staff will remain at their current location in Munich which will serve as a hub for ADC innovation for Gilead as a whole.
